Gyre Therapeutics
GYRE
89 hedge funds and large institutions have $113M invested in Gyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 9 closing their positions.
406% more call options, than puts
Call options by funds: $2.92M | Put options by funds: $577K
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
25% more capital invested
Capital invested by funds: $90.2M → $113M (+$22.7M)
11% more funds holding
Funds holding: 80 → 89 (+9)
0.91% more ownership
Funds ownership: 8.63% → 9.54% (+0.91%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12.9M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$9.85M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.71M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$6.09M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.66M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.55M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.36M |
| 4 |
Renaissance Technologies
New York
|
-$918K |
| 5 |
Millennium Management
New York
|
-$882K |
GYRE Hedge Fund Activity: Q1 2021 in Review
89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2021, worth a combined $113M — up 25% from $90.2M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GYRE positions and 9 closed out — a net gain of 9 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $12.9M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.66M sold.
- 89 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2021, up from 80 in Q4 2020.
- Funds reported $113M of Gyre Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
- 18 funds opened new Gyre Therapeutics positions in Q1 2021 and 9 closed out, a net change of +9 holders.
- The largest Gyre Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $12.9M added.
- The largest Gyre Therapeutics seller in Q1 2021 was AIGH Capital Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2021.